UPDATE: Needham & Company Starts RxSight Inc. (RXST) at Buy

Needham & Company analyst David Saxon initiates coverage on RxSight Inc. (NASDAQ: RXST) with a Buy rating and a price target of $18.00.

The analyst comments "The RxSight System is a differentiated intraocular lens (IOL) that can result in better visual outcomes for the patient. We believe this could drive adoption despite the incremental capital equipment required. Our doctor checks (doc diligence) suggest RXST's IOL could be appropriate for up to ~20% of the cataract patient population (vs. RXST's 2021 US market share of ~0.7%). We believe shares are attractively valued considering RXST's growth profile, and initiate coverage with a Buy rating and an $18 price target."

For an analyst ratings summary and ratings history on RxSight Inc. click here. For more ratings news on RxSight Inc. click here.

Shares of RxSight Inc. closed at $13.51 yesterday.

You May Also Be Interested In

• Coherent (COHR) PT Raised to $420 at Needham
• Veritone (VERI) PT Lowered to $5 at Needham
• RxSight Inc. (RXST) PT Lowered to $7 at Stifel Amid U.S. Adoption Challenges